UCB's bimekizumab meets in Phase IIb for ankylosing spondylitis

UCB S.A. (Euronext:UCB) reported data from the Phase IIb BE AGILE trial in 303 patients with active ankylosing spondylitis showing that subcutaneous bimekizumab

Read the full 237 word article

User Sign In